How Long Does Enhertu Stay in Your System?

Enhertu (trastuzumab deruxtecan, also called T-DXd) has a half-life of roughly six days, which means the intact drug takes about a month to clear from your bloodstream after the last infusion.¹ That straightforward number, though, only tells part of the story. Enhertu is an antibody-drug conjugate, a two-part molecule whose components behave differently once they separate inside the body, and some of its biological effects persist well beyond the point when standard blood tests can detect the drug.

What a Six-Day Half-Life Means in Practice

A half-life of about six days means that six days after an infusion, roughly half the intact Enhertu molecules are still circulating. After another six days, about a quarter remain. Pharmacologists generally consider a drug functionally cleared after four to five half-lives, so for Enhertu that works out to roughly 24 to 30 days after the last dose. Because Enhertu is dosed every three weeks, the drug never fully leaves your system between infusions during active treatment. Each new dose is added on top of whatever remains from previous cycles, and the drug reaches a steady concentration after several cycles.

This steady-state behavior is why oncologists think about Enhertu exposure in terms of cycles rather than single doses. If you stop treatment, the clock on clearance starts from that final infusion. For most patients, the intact conjugate will be essentially undetectable in blood roughly a month later. But the antibody portion and the released chemotherapy payload each follow their own timelines, which is why the full picture is more layered than a single half-life number suggests.

The Two Parts of the Molecule Clear Differently

Enhertu is built from two components joined by a cleavable chemical linker. The first component is trastuzumab, the same antibody backbone used in Herceptin, which targets HER2 receptors on tumor cells. The second is DXd, a potent chemotherapy payload derived from exatecan. Once Enhertu binds to a HER2-expressing cell and gets pulled inside, enzymes cut the linker and release DXd to kill the cell. But some of that payload also gets released in the bloodstream before the drug ever reaches a tumor cell.

In animal studies, the drug-to-antibody ratio of Enhertu, a measure of how many payload molecules are still attached to each antibody, dropped by about half within seven days of dosing.² That means the antibody is shedding its chemotherapy cargo steadily over the first week. The released DXd itself has a much shorter half-life in the blood, on the order of hours rather than days. So the free payload clears quickly once it detaches, but the antibody keeps releasing new payload for days. This is partly why side effects like nausea can persist between infusion cycles even when the peak of free DXd in blood has long passed.

The antibody shell, once stripped of its payload, behaves like other large therapeutic antibodies. It is broken down through two main routes: it binds to HER2 receptors on cells and gets internalized, and it is also taken up by immune cells that recognize the antibody’s constant region.³ Both pathways break it down into amino acids that the body recycles normally.

How Enhertu Leaves the Body

Unlike many small-molecule drugs that are processed mainly by the liver and excreted through the kidneys, Enhertu follows the clearance pathway typical of antibody-based therapies. The intact conjugate and the antibody component are too large to be filtered by the kidneys. Instead, Enhertu and its breakdown products are eliminated primarily through bile and feces, with very little showing up in urine.³ The drug distributes in a two-compartment pattern, moving between the bloodstream and body tissues, with body weight being the main factor that affects how it distributes.

This biliary excretion route has a practical implication: liver health matters more than kidney health when it comes to Enhertu’s clearance. That said, population studies of patients with varying levels of kidney and liver function have not found clinically meaningful differences in how much drug exposure people actually get at steady state.⁴ The thresholds tested in those analyses were mild-to-moderate impairment, so patients with severe liver or kidney disease represent a less well-studied group. But for the majority of patients, Enhertu’s clearance rate is surprisingly consistent.

Do Patient Factors Change How Long It Stays?

One of the reassuring findings from pharmacokinetic studies is that Enhertu’s behavior in the body does not vary much across different patient groups. Researchers have stratified patients by country, race, kidney function, and liver function and found no differences large enough to warrant changing the dose.⁴ Body weight is the most influential covariate, and since Enhertu is dosed by weight (5.4 mg per kilogram), that variability is already accounted for in how the dose is calculated.

This means you don’t need to worry that your age, ethnicity, or mild organ impairment is causing the drug to linger unusually long or clear unusually fast. The six-day half-life and the roughly one-month clearance window after the last dose apply broadly. Where things get murkier is in patients who have significant liver disease beyond what has been formally studied, or in the very elderly with multiple organ systems declining simultaneously. In those cases, oncologists typically monitor more closely rather than adjusting the dose, since the formal data have not shown a need for adjustment within the populations tested.

Why Side Effects Can Last Longer Than the Drug Itself

This is where the question “how long does Enhertu stay in your system” gets genuinely complicated, because the drug’s biological footprint extends well past its pharmacokinetic elimination. The most concerning example is interstitial lung disease, or ILD, a form of lung inflammation that is Enhertu’s most serious known side effect and carries a black box warning on the label.⁵

In clinical trials, the median time to the first sign of ILD was 81 days from the start of treatment, with some cases appearing as early as the first day and others not surfacing until nine months in.⁶ Once ILD develops and the drug is stopped, the median time to resolution was 44 days, but some patients took over eight months to recover.⁶ This means lung inflammation from Enhertu can persist for months after the last molecule of drug has left the bloodstream.

Animal research helps explain why. In mouse models, lung tissue examined one and two weeks after the final dose of trastuzumab deruxtecan showed progressive damage including thickening of the tissue between air sacs, inflammatory cell infiltration, and early scarring. The worst damage appeared at two weeks post-dosing, not during treatment, suggesting that the inflammatory process continues to escalate even as the drug itself is being cleared.⁷ The pattern was consistent across species, matching what has been observed in primate studies as well.⁷

Other side effects follow their own timelines. Nausea, which affects a large proportion of patients, tends to peak within the first few days of each cycle and usually eases before the next infusion. Hair loss, fatigue, and low blood counts all have their own rhythms, but they are tied to the payload’s effects on dividing cells. Since Enhertu keeps releasing DXd for days after each infusion, these effects can stretch across the full three-week cycle. After treatment ends, most of these symptoms begin to improve within a few weeks, though fatigue can linger for months in some people for reasons that go beyond drug clearance alone.

Timing Around Surgery and Pregnancy

If you’re stopping Enhertu before surgery, your oncologist will typically want several half-lives to pass before operating. The concern is twofold: the chemotherapy payload can impair wound healing and suppress the immune system’s ability to fight post-surgical infection, and the intact drug could interfere with tissue that needs to recover. A washout period of at least four to five weeks after the last dose is a common practical guideline, though the exact timing depends on the type of surgery and your overall health.

For pregnancy planning, the stakes are higher and the recommended waiting period is longer. Trastuzumab, the antibody backbone of Enhertu, is known to cause harm to a developing fetus, particularly to kidney development. The DXd payload is a chemotherapy agent that can damage rapidly dividing cells, which includes embryonic and fetal tissue. Prescribing information for Enhertu recommends effective contraception during treatment and for at least seven months after the last dose for people who can become pregnant. That seven-month window is far longer than the pharmacokinetic clearance period and is designed to provide a wide safety margin, since even trace amounts of payload or antibody during early pregnancy could pose risks.

Partners who produce sperm are also advised to use contraception for a period after treatment, since the DXd payload has the potential to damage sperm DNA. The recommended duration is shorter, but the principle is the same: the concern isn’t whether intact drug is still circulating, but whether the payload has caused genetic damage to reproductive cells that takes time to cycle out.

How Enhertu Compares to Older HER2-Targeted Drugs

Patients often ask about Enhertu’s persistence relative to other HER2-directed therapies they may have received earlier. Trastuzumab alone (Herceptin) has a half-life that varies with dose but is generally longer, falling somewhere in the range of one to four weeks depending on the dosing schedule. However, trastuzumab does not carry a chemotherapy payload, so the concern about lingering drug effects is mostly limited to cardiac monitoring rather than the broader toxicity profile that comes with Enhertu’s attached DXd.

Ado-trastuzumab emtansine (Kadcyla, or T-DM1), the older antibody-drug conjugate that predated Enhertu, uses a different linker chemistry and a different payload. Its linker is more stable, meaning the payload stays attached to the antibody longer and is released primarily inside cells. Enhertu’s linker is designed to be more readily cleaved, which is partly why DXd can produce a “bystander effect,” killing nearby tumor cells that don’t express HER2 themselves. But that cleavability also means more payload gets released in circulation, contributing to systemic side effects. The rat data showing a roughly 50 percent drop in drug-to-antibody ratio within a week reflect this design trade-off.²

Practically, this means that after stopping Enhertu, the chemotherapy payload washes out of the blood faster than you might expect given the antibody’s six-day half-life, because DXd detaches and is eliminated on its own much quicker timeline. But the antibody shell lingers, and the tissue-level effects of the payload, especially in the lungs, can persist independently of what’s measurable in a blood draw.

Monitoring After Your Last Dose

Because ILD can appear or worsen after treatment ends, oncology guidelines recommend continued monitoring for respiratory symptoms even after you stop receiving Enhertu. New or worsening cough, shortness of breath, or fever in the weeks to months after your last infusion should prompt a call to your care team, not be dismissed as leftover treatment effects. The median onset of ILD at 81 days from the start of treatment means that for patients who receive only a few cycles, the first sign of lung trouble might not appear until after they’ve already stopped the drug.⁶

Cardiac monitoring is also part of the follow-up picture. While Enhertu does not carry the same black box cardiac warning as some other HER2-targeted agents, reductions in heart pumping function have been observed in a small percentage of patients.⁵ Echocardiograms or similar imaging are typically performed at intervals during and after treatment. These cardiac effects, when they occur, can also outlast the drug’s presence in blood, since the heart muscle may take time to recover from any injury sustained during treatment.

Blood counts, liver enzymes, and other routine labs will generally normalize within a few weeks of stopping Enhertu, in line with the drug’s clearance timeline. If your labs are still trending in the wrong direction a month or more after the last infusion, that’s worth flagging to your oncologist, since it suggests something other than residual drug may be contributing.

The Bystander Effect and Tissue-Level Persistence

One feature of Enhertu that makes the question of “how long it stays” harder to answer cleanly is the bystander effect. When DXd is released from the antibody inside a tumor cell, some of that payload leaks out and enters neighboring cells, including cells that don’t have HER2 on their surface. This is actually a feature, not a bug, as it helps Enhertu kill tumors that have a mix of HER2-positive and HER2-negative cells. But it also means the payload’s effects are distributed across tissues in ways that a simple blood-level measurement doesn’t capture.

DXd is membrane-permeable, meaning it can pass in and out of cells relatively freely. Once inside a cell, it inhibits an enzyme involved in DNA replication, which triggers cell death. In tumor tissue, this is the desired effect. In normal tissue, it contributes to side effects. Importantly, the drug can be doing its work inside cells at the tissue level even when blood concentrations of free DXd are low or undetectable. This is why patients sometimes experience nausea, mouth sores, or fatigue that seems disproportionate to what their blood work might suggest about residual drug levels.

After treatment stops, the tissue-level effects wind down as damaged cells are cleared and replaced. For most tissues, this takes days to weeks. For the lungs, as the ILD data show, the timeline can stretch to months. The body’s inflammatory response to damaged lung tissue can become self-sustaining for a period, continuing to cause symptoms even in the complete absence of any drug. This is part of why ILD from Enhertu is treated with corticosteroids rather than simply waiting for the drug to clear. The inflammation has taken on a life of its own and needs to be actively suppressed.

1
Australian Prescriber. Trastuzumab deruxtecan for breast cancer
2
PubMed Central. Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
3
Expert Opinion on Drug Metabolism & Toxicology. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer
4
PubMed Central. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors
5
PubMed Central. Breast Cancer Immunotherapy: A Clinical Review for the Plastic Surgeon
6
The Journal of Hematology Oncology Pharmacy. Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan
7
npj Precision Oncology. Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease